Epix Pharmaceuticals

Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts.

Its products included the following agents:[citation needed]

  • PRX-00023—5-HT1A receptor full agonist (later discovered to be an antagonist): for major depression and generalized anxiety disorder
  • PRX-03140—5-HT4 receptor partial agonist: for Alzheimer's disease
  • PRX-07034—5-HT6 receptor antagonist: for obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia
  • PRX-08066—5-HT2B receptor antagonist: for pulmonary hypertension associated with chronic obstructive pulmonary disease

As of July 2009, the company was in the process of asset liquidation due to insufficient funds to stay afloat.[1]

References

  1. ^ Weisman, Robert (22 July 2009). "Epix Pharmaceuticals of Lexington is latest biotech to fall to funding crunch". The Boston Globe. Retrieved 23 November 2011.

External links

  • EPIX Pharmaceuticals, Inc. web site
  • v
  • t
  • e
Pharmaceutical companies of the United States
Current
Former
Tax inversion
Other
Authority control databases Edit this at Wikidata
  • ISNI


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e